Yale University Jul 4 2025 Cancer fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the tumor threat and traditional immune therapies, revealing the need for new targets and treatments. Those are among the results described in a July 2 published report in the Journal of Clinical Oncology that set out to understand the biology of certain kidney tumors,